pomalidomide has been researched along with Neoplasms, Plasma Cell in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Lee, K; Matous, J; Mouro, J; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K | 1 |
| Aebi, S; Driessen, C; Goede, J; Hayoz, S; Lerch, E; Maniecka, Z; Mey, U; Novak, U; Pabst, T; Renner, C; Rhyner Agocs, G; Rüfer, A; Schär, S; Zander, T | 1 |
| Mollee, P; Scott, AP | 1 |
2 trial(s) available for pomalidomide and Neoplasms, Plasma Cell
| Article | Year |
|---|---|
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasms, Plasma Cell; Quality of Life; Thalidomide | 2022 |
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasms, Plasma Cell; Thalidomide | 2023 |
1 other study(ies) available for pomalidomide and Neoplasms, Plasma Cell
| Article | Year |
|---|---|
Pomalidomide - Author Reply.
Topics: Australia; Humans; Multiple Myeloma; Neoplasms, Plasma Cell; Thalidomide | 2019 |